Contineum Therapeutics
CTNM · NASDAQ · Health Care · Pharmaceutical Preparations
Pharmaceutical Preparations company based in San Diego, Ca.
As of Oct 20, 2026, OQRO holds for Contineum Therapeutics (CTNM) over the last 12 months: 0 insider filings, 0 Congress trades, 10 fund positions and 0 federal contract awards. Most recent on file: Longaeva Partners L.P. disclosed a new position in CTNM for Q4 2025, filed Feb 17, 2026.
On the public record for Contineum Therapeutics over the 12 months to Oct 20, 2026: 1 clinical trial.
Example public filing
Longaeva Partners L.P. opened a new position $5.37M
Longaeva Partners L.P. opened a new position in Contineum Therapeutics, per its Q4 2025 13F.
- 470K
- Shares reported
- 0.45%
- Disclosed portfolio weight
- $5.37M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- Feb 17, 2026
Data as of Oct 20, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for CTNM, last 12 months
- 0
- Insider filings
- 0
- Congress trades
- 10
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2024
Insiders of Contineum Therapeutics reported 0 open-market purchases and 3 sales since 2024; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | 3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
10 records for Contineum Therapeutics in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
3 days free for first-time subscribers, then $9.99 a month. Nothing is charged today: your card is charged when the trial ends unless you cancel before, from your account. Secure payment by Stripe.
Public previews are free. Full research is OQRO Pro, with a 3-day free trial to start: your card is charged only when the trial ends.
Free account: get the written context of this page, built from its filings.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Contineum Therapeutics insider trading
Have Contineum Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Contineum Therapeutics is on record in SEC filings since 2006.
How often do Contineum Therapeutics insiders buy and sell shares?
Since 2024, Contineum Therapeutics insiders reported 0 open-market purchases and 3 sales on Forms 4 and 5.
Do members of Congress trade CTNM?
No trade in Contineum Therapeutics (CTNM) was disclosed by a member of Congress in the last 12 months.
When does Contineum Therapeutics report its next results?
Contineum Therapeutics's next results are expected on Oct 28, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.